Cell Cycle · 2018 · 60 citations · 22 references
Life SciencesCancer BiologyMolecular BiologyCell CycleGene ExpressionMolecular OncologyCell Cycle DeregulationCell-cycle CheckpointsMicrorna-mediated RegulationRna InterferenceTumor BiologyUntranslated RegionsCell Cycle DynamicsCell Cycle InhibitionMicrorna-mediated OncogenesisMicrorna-mediated ResistanceOncogenic Cell-cycle Reprogramming
Although epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) gefitinib has exhibited notable clinical efficacy in non-small cell lung cancer (NSCLC) patients. However, its therapeutic efficacy is ultimately limited by the development of gefitinib resistance. The present study aimed to investigate the effects of the long non-coding RNA, RHPN1-AS1 on gefitinib resistance in NSCLC and explore the underlying mechanisms. In this study, RHPN1-AS1 was observed to be downregulated in gefitinib resistant patients and NSCLC cell lines. Besides, decreased expression of RHPN1-AS1 was found to be associated with poor prognosis of NSCLC patients. RHPN1-AS1 knockdown conferred gefitinib resistance to gefitinib sensitive NSCLC cells, whereas the overexpression of RHPN1-AS1 sensitized gefitinib resistant NSCLC cells to gefitinib treatment. Mechanistically, RHPN1-AS1 was found to positively regulate the expression of TNFSF12 by directly interacting with miR-299-3p. Collectively, RHPN1-AS1 modulates gefitinib resistance through miR-299-3p/TNFSF12 pathway in NSCLC. Our findings indicate that RHPN1-AS1 may serve as not only a prognostic biomarker for gefitinib resistance but also as a promising therapeutic biomarker and target for the treatment of NSCLC patients.
22
A ceRNA Hypothesis: The Rosetta Stone of a Hidden RNA Language?
Leonardo Salmena, Laura Poliseno, Yvonne Tay et al. · Cell · 2011 · 7.7K citations · Full text
Jean‐Charles Soria, Yi‐Long Wu, Kazuhiko Nakagawa et al. · The Lancet Oncology · 2015 · 410 citations
Medicine, Oncology, Pharmacology +15
Identification of a ligand for the death-domain-containing receptor Apo3
Scot A. Marsters, James P. Sheridan, Robert Pitti et al. · Current Biology · 1998 · 186 citations · Full text
EGFR-TKI resistance in NSCLC patients: mechanisms and strategies.
Yuxin Lin, Xian Wang, Hongchuan Jin · PubMed · 2014 · 183 citations
Medicine, Oncology, Pharmacology +17
Siyuan Dong, Xiaohan Qu, Wenya Li et al. · Journal of Hematology & Oncology · 2015 · 171 citations · Full text
Medicine, Oncology, Pharmacology +17